Vistin Pharma Asa · OSL:VISTN

Vistin Pharma Asa — Investor Presentation (June 2015)

10 slides from Vistin Pharma Asa's investor presentation, Jun 10, 2015

  1. Slide 1: Vistin Pharma ASA

    Vistin Pharma ASA Oslo Børs 10 June 2015 1

  2. Slide 2: This is Vistin Pharma

    COMPANY OVERVIEW This is Vistin Pharma Overview Key financials (NOK million)  Leading producer of active ingredients for diabetes medicine (metformin) and opiates for use in pain relief 242 and cough medicine 229 199  Significant contract manufacturer (CMO) of solid dosage 170 form (tablets) produ

  3. Slide 3: Metformin: First line treatment of type 2 diabetes

    METFORMIN First line treatment of type 2 diabetes Vistin Pharma metformin overview Global manufacturing capacity – Metformin HCI Vistin Pharma ~8%  Producer of three different metformin API products - Metformin HCl (bulk API, “fine, dry powder”) - Metformin DC (“directly compressible”, a granulated

  4. Slide 4: Diabetes - The Global Epidemic

    METFORMIN Diabetes - The Global Epidemic  Diabetes is estimated to grow 55% from 2013 to 2035  Largest growth in developing economies Source: IDF (International Diabetes Federation) 4

  5. Slide 5: Expected foreseeable annual metformin volume growth of 7-8%

    METFORMIN Expected foreseeable annual metformin volume growth of 7-8%  Metformin consumption in 2013 Type 2 diabetes (T2D) corresponds to  Represents about 90% of diabetes cases - treatment of ~50% of diagnosed population and - ~25% of total population with T2D  46% of total T2D population estima

  6. Slide 6: Value proposition in the metformin market

    METFORMIN Value proposition in the metformin market Two key characteristics placing Vistin Pharma in a unique position within the metformin market Operational excellence Aim to dominate the high value customer segment  Provides among the purest and most free-flowing qualities  Focus on reliable su

  7. Slide 7: Major opioids "powder-to-pill" supplier

    OPIOIDS Major opioids “powder-to-pill” supplier Overview Global manufacturing capacity  Drugs delivered from opium and their chemically Codeine market Pholcodine market related derivatives Vistin Pharma Vistin Pharma ~7% - Opioids is a group of natural and synthetic drugs with ~16% morphine-like pr

  8. Slide 8: Stable growth in the use of opioids

    OPIOIDS Stable growth in the use of opioids Growth driven by developing countries Competitive situation - high entry barriers  Aging population and rising prevalence of diseases  Only a few companies are allowed to manufacture - Demand, measured by defined daily doses, has increased 3.5 opioids ti

  9. Slide 9: Unique position in today's codeine market

    OPIOIDS Unique position in today’s codeine market driven by… Vistin Pharma: …the industry’s unusual key features…  Established market share of ~30% in the UK –  Tight regulatory controls create high entry barriers the largest codeine market in Europe - eliminates the risk of low cost Asian competi

  10. Slide 10: Vistin Pharma - a CMO tablet manufacturer

    3RD PARTY CMO Vistin Pharma - a CMO tablet manufacturer Vistin Pharma has a CMO agreement with Weifa Preliminary estimated key financials  Contract manufacturer agreement (CMO) with Weifa for 2015 full year basis the production of Weifa’s key pain relief brands  Revenues: approximately NOK 110 - 1

Vistin Pharma — Investor Presentation (June 2015) on 6ix